Comparative Pharmacology
Head-to-head clinical analysis: CYPROHEPTADINE HYDROCHLORIDE versus POLARAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYPROHEPTADINE HYDROCHLORIDE versus POLARAMINE.
CYPROHEPTADINE HYDROCHLORIDE vs POLARAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyproheptadine is a potent antihistamine (H1 receptor antagonist) and antiserotonergic agent (5-HT2 receptor antagonist). It also exhibits weak anticholinergic and sedative properties. It blocks histamine-mediated vasodilation, increased capillary permeability, and pruritus, as well as serotonin-mediated effects on appetite and mood.
Competitive antagonist of histamine H1 receptors, blocking the effects of histamine in the respiratory tract, vasculature, and gastrointestinal tract.
4 mg orally three times daily; range 4-20 mg/day, not to exceed 0.5 mg/kg/day
4-8 mg orally every 6-8 hours; maximum 24 mg/day.
None Documented
None Documented
Terminal half-life approximately 8–16 hours in adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life: 20-25 hours (range 14-36 hours). Clinical context: Supports once-daily dosing for chronic allergic symptoms; accumulation possible with hepatic impairment.
Primarily renal (appreciable unchanged drug and metabolites); biliary/fecal elimination minor (<5%).
Primarily renal (40-60% as unchanged drug and metabolites), with minor biliary/fecal elimination
Category A/B
Category C
Antihistamine
Antihistamine